About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Breaking News:
Verrica announced the approval of YCANTHâ„¢ (cantharidin) topical solution 0.7%
Document Details
Form: SC 13D
Filing Date: July 15, 2022
Document Date: July 15, 2022
Form Description: Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Group:
Other
Company: Verrica Pharmaceuticals
Filing Formats
View HTML
Download PDF
Download DOC
Download XLS
BREAKING NEWS:
Verrica announced the approval of YCANTH (cantharidin) topical solution
Learn More
Please see
Important Safety Informa
tion
and full
Prescribing Information